Introduction
============

Chronic obstructive pulmonary disease (COPD) affects between 12 and 24 million people in the United States, where it is the fourth leading cause of death, accounting for over 106,000 deaths in 1996. Worldwide, COPD is the sixth leading cause of death ([@b177-copd-3-331]; [@b257-copd-3-331]; [@b72-copd-3-331]; [@b73-copd-3-331]; [@b269-copd-3-331]) and is the only condition in the top 10 causes of death with an increasing prevalence and mortality ([@b174-copd-3-331]; [@b131-copd-3-331]; [@b177-copd-3-331]; [@b227-copd-3-331]). The Global Burden of Disease study undertaken by the World Bank and the World Health Organization concluded that COPD will become the third leading cause of death worldwide by 2020, and its ranking relative for number of disability-adjusted life-years lost will increase from 12th to 5th ([@b70-copd-3-331]). Currently, oxygen therapy for hypoxemic patients and cigarette-smoking cessation are the only interventions known to alter the natural history of COPD.

Although an exact definition of acute exacerbations of COPD (AECOPD) remains controversial ([@b173-copd-3-331]), a generally accepted definition is that of 'a sustained worsening of the patient's condition, from the stable state and beyond normal day-today variations, that is acute in onset and necessitates a change in regular medication in a patient with underlying COPD' ([@b186-copd-3-331]). Acute exacerbations of COPD (AECOPD) account for about 13 million office visits each year in the US ([@b157-copd-3-331]; [@b210-copd-3-331]; [@b67-copd-3-331]), and account for 31%--68% of the total cost of COPD in the US and Europe ([@b257-copd-3-331]; [@b136-copd-3-331]; [@b229-copd-3-331]; [@b11-copd-3-331]; [@b142-copd-3-331]). In 1996, acute exacerbations of COPD resulted in the sixth highest use of hospital bed days/yr in the US (176 million) and the sixth highest number of days lost from work (57.5 million) ([@b52-copd-3-331]). As such, AECOPDs are a major source of health-care expenditure ([@b73-copd-3-331]). This cost is particularly evident in those AECOPDs that require hospitalization ([@b142-copd-3-331]; [@b168-copd-3-331]).

The negative implications of AECOPDs have been highlighted by numerous investigators. A review of eighteen studies confirmed that AECOPD worsen health-related quality of life (HRQL) ([@b206-copd-3-331]). A two-year longitudinal study noted that more frequent exacerbations had a deleterious effect on health status in patients with moderate disease (forced expiratory volume in one second \[FEV~1~\] 35%--50% predicted) ([@b139-copd-3-331]). The greatest improvement in HRQL occurs during the first four weeks after a single episode, although continued improvement occurs over 26 weeks. Conversely, recurrence of AECOPD markedly attenuates improvement ([@b224-copd-3-331]).

AECOPDs also result in measurable, albeit modest, acute effects on pulmonary function ([@b209-copd-3-331]). A modest improvement in pulmonary function, particularly in lung volume, has been reported over the first several weeks after therapy is initiated ([@b170-copd-3-331]; [@b225-copd-3-331]) Repeated AECOPDs are associated with loss of pulmonary function; the decrement in FEV~1~ has ranged from 7--8 mL/yr for patients with more frequent episodes ([@b49-copd-3-331]; [@b106-copd-3-331]).

Thus, AECOPD are associated with very significant healthcare expenditures, deterioration in HRQL that may be sustained, and appreciable deterioration in pulmonary function. Accordingly, preventing AECOPDs, or reducing their severity, should have favorable clinical, physiological and economical effects in COPD patients.

COPD is an inflammatory disease
===============================

Over the past several years, numerous studies have confirmed the important role of inflammation in the airways and lung parenchyma of COPD ([@b78-copd-3-331]; [@b211-copd-3-331]; [@b1-copd-3-331]; [@b66-copd-3-331]; [@b259-copd-3-331]; [@b178-copd-3-331]; [@b261-copd-3-331]). Many have advocated a central pathogenic role of this inflammatory response ([@b83-copd-3-331]; [@b215-copd-3-331]; [@b244-copd-3-331]; [@b270-copd-3-331]). This inflammatory response contributes to the increased oxidative stress noted during an AECOPD ([@b251-copd-3-331]). Both neutrophilic and eosinophilic inflammation have been described, with a multitude of inflammatory mediators implicated including interleukin-8 (IL-8), leukotriene B4 (LTB~4~), tumor necrosis factor-α (TNF-α), granulocyte-macrophage colony stimulating factor (GMCSF), regulated upon activation: normal T cell expressed/secreted (RANTES), and endothelin-1 (ET-1) ([@b78-copd-3-331]; [@b211-copd-3-331]; [@b66-copd-3-331]; [@b187-copd-3-331]; [@b261-copd-3-331]). One group followed 68 patients with COPD and an emphysematous phenotype for 2--3 years, with 30 developing an AECOPD associated with expectorated sputum adequate for analysis ([@b60-copd-3-331]). During an AECOPD, total sputum cells, lymphocytes, neutrophils, eosinophils, IL-8, neutrophil elastase, eosinophilic cationic protein (ECP), and RANTES increased compared to the stable state. Prospective studies using bronchoscopic techniques have confirmed increased expression of RANTES in both the surface epithelium and subepithelial lymphomononuclear cells, increased numbers of neutrophils, as well as increases in CXCL5 (ENA-87), CXCL8 (IL-8), and CXCR2 during an AECOPD ([@b277-copd-3-331]; [@b180-copd-3-331]; [@b51-copd-3-331]). Collectively, these data confirm a local, inflammatory process and increased oxidant stress status during exacerbations. Novel pathways promulgating this inflammatory response have recently been defined ([@b95-copd-3-331]).

As COPD progresses, the lungs are infiltrated by activated macrophages ([@b193-copd-3-331]; [@b10-copd-3-331]; [@b33-copd-3-331]) and lymphocytes ([@b195-copd-3-331]; [@b169-copd-3-331]; [@b83-copd-3-331]). Macrophages and lymphocytes, are not only increased in the airways and alveoli in COPD ([@b46-copd-3-331]; [@b215-copd-3-331]), but the prevalence of these two cell types, rather than of neutrophils as previously suspected, correlates with the severity of airflow obstruction ([@b47-copd-3-331], [@b45-copd-3-331]; [@b169-copd-3-331]; [@b111-copd-3-331]; [@b79-copd-3-331]; [@b252-copd-3-331]; [@b83-copd-3-331]) and emphysema ([@b57-copd-3-331]; [@b191-copd-3-331]; [@b192-copd-3-331]).

Macrophages are key cells of the innate immune system, secreting cytokines and chemokines when stimulated by pathogen-associated molecular patterns (PAMPs). Many of the lung lymphocytes are type 1 cytokine-producing CD8 T cells ([@b196-copd-3-331], [@b194-copd-3-331], [@b197-copd-3-331]; [@b130-copd-3-331]; [@b69-copd-3-331]). The CD8+ T cells predominance has been most evident in studies that used chronic bronchitis as an entry criteria ([@b198-copd-3-331]), and is less evident when study design selected *against* chronic bronchitis ([@b83-copd-3-331]). Although macrophages and CD8+ T cells could synergistically contribute to progressive lung destruction in COPD in several ways ([@b24-copd-3-331]), the exact mechanism remains unproven. The systemic nature of COPD and AECOPDs have been recently documented ([@b5-copd-3-331]). Plasma fibrinogen, IL-6, C-reactive protein, and endothelin-1 concentrations increase during AECOPDs ([@b43-copd-3-331]; [@b258-copd-3-331]; [@b187-copd-3-331]; [@b85-copd-3-331]).

Lung infections increase the inflammation of COPD
=================================================

Various infectious and noninfectious stimuli can stimulate the inflammatory response associated with an AECOPD. Environmental pollutants, including particulate matter and nonparticulate gases can provoke an inflammatory response in-vitro and in in-vivo ([@b44-copd-3-331]; [@b165-copd-3-331]; [@b190-copd-3-331]). Epidemiological studies have suggested increased respiratory symptoms and mortality during times of increased air pollution ([@b230-copd-3-331]; [@b62-copd-3-331]; [@b231-copd-3-331]). Despite these data, a large proportion of AECOPDs are felt to reflect infection, whether bacterial or viral ([@b212-copd-3-331]). Viral infections are a well recognized cause of AECOPD ([@b262-copd-3-331]; [@b99-copd-3-331]). The most frequently reported agents include rhinovirus, coronavirus, influenza, parainfluenza, adenovirus, respiratory syncytial virus (RSV), and human metapneumovirus ([@b228-copd-3-331]; [@b71-copd-3-331]; [@b207-copd-3-331]; [@b68-copd-3-331]; [@b183-copd-3-331]; [@b242-copd-3-331]; [@b179-copd-3-331]; [@b260-copd-3-331]; [@b75-copd-3-331]).

Atypical infectious agents, including *Chalmydia pneumoniae*, *Mycoplasma pneumoniae,* and *Legionella* species, have been reported to cause AECOPD, although the majority of the data involve *C. pneumoniae* ([@b27-copd-3-331]; [@b30-copd-3-331]; [@b144-copd-3-331]; [@b107-copd-3-331]; [@b128-copd-3-331]; [@b208-copd-3-331]). The etiologic role of bacteria in individual AECOPD episodes has been a subject of much controversy ([@b81-copd-3-331]; [@b151-copd-3-331]). Recent comprehensive reviews have highlighted the evolution of these concepts ([@b214-copd-3-331]; [@b212-copd-3-331]). Sputum cultures have been the classic methodological approach to identifying potentially pathogenic bacteria in AECOPD, with the most frequently isolated organisms being nontypeable *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Streptococcus pneumoniae*. Other, less frequently identified organisms include *Haemophilus parainfluenzae*, *Staphylococcus aureus*, *Pseudomonas aeruginosa* and other Gram-negative rods. *Pseudomonas spp.* or other enteric Gram-negative rods have been identified in the sputum of patients with greater airflow obstruction ([@b53-copd-3-331]; [@b138-copd-3-331]) and prior use of antimicrobial agents ([@b146-copd-3-331]).

Bronchoscopic studies using bronchoalveolar lavage or protected specimen brush have confirmed that potentially pathogenic bacteria are identified in many COPD patients at baseline and during AECOPDs ([@b56-copd-3-331]; [@b147-copd-3-331]; [@b176-copd-3-331]; [@b222-copd-3-331]). An analysis of pooled data from six published studies confirmed a high frequency of colonization in stable COPD patients in contrast with healthy subjects; a clear shift to higher potentially pathogenic organism load was noted during an AECOPD ([@b188-copd-3-331]). Importantly, several groups have demonstrated that bacterial colonization, as defined by sputum cultures, is associated with a greater sputum and systemic inflammatory response, more frequent clinical AECOPD episodes and greater symptoms and worse health status ([@b221-copd-3-331]; [@b32-copd-3-331]; [@b79-copd-3-331]; [@b172-copd-3-331]; [@b21-copd-3-331]).

Novel methodological approaches have provided even more compelling data implicating bacterial pathogens in AECOPD. The longitudinal use of sputum culture and molecular typing of bacterial pathogens isolated from sputum has demonstrated that acquisition of a bacterial strain with which the patient had not been previously infected is associated with a greater than twofold increase in the risk of an exacerbation ([@b213-copd-3-331]). Although the identification of a new strain of nontypeable *H. influenzae* was not associated with a symptomatic exacerbation in the majority of patients, collaborative work has highlighted inherent differences in new *H. influenzae* strains associated with symptomatic exacerbations which lead to greater neutrophil recruitment, adherence to epithelial cells and greater IL-8 release from epithelial cell cultures compared to those not associated with such a clinical response ([@b34-copd-3-331]). A similar approach has confirmed the same increased risk of AECOPD for *M. catarrhalis* ([@b150-copd-3-331]).

An immune response to one or more microbial pathogens has been utilized recently to define further the role of bacteria in individual AECOPD episodes. This methodological approach has been most widely reported for *H. influenzae* and *M. catarrhalis* ([@b152-copd-3-331]; [@b275-copd-3-331]; [@b18-copd-3-331]; [@b212-copd-3-331]; [@b150-copd-3-331]), and to examine the interaction between bacterial and viral infection ([@b20-copd-3-331]). In one such study, 16/35 exacerbations (46%) were associated with evidence of acute viral infection, whereas 11 (31%) were associated with the development of new serum IgG to homologous *H. influenzae* isolates; evidence of a viral infection was identified in 24/35 exacerbations (79%) ([@b20-copd-3-331]). These data show that viral and bacterial infections can co-exist during symptomatic AECOPD, although antecedent viral infection is not required for *H. influenzae-* associated exacerbations.

Macrolides in COPD
==================

Treatment of AECOPD
-------------------

Given compelling data that bacterial infection is likely etiologic in approximately 50% of AECOPDs, it is not surprising that antimicrobial therapy has been intensively studied in this disease. Numerous placebo-controlled trials of antibiotics in AECOPDs have been published, with systematic reviews suggesting a modest treatment effect favoring antimicrobial therapy ([@b17-copd-3-331]; [@b135-copd-3-331]; [@b202-copd-3-331]). Saint and colleagues (2005) examined nine placebo controlled trials and concluded that there was a small but statistically significant improvement with antibiotic therapy, which was especially significant in patients with low baseline flow rates. The American College of Chest Physicians, American College of Physicians, and the American Society for Internal Medicine systematically analyzed 11 randomized, placebo-controlled studies of antibiotic treatment and also concluded that antibiotics are beneficial ([@b17-copd-3-331]; [@b135-copd-3-331]; [@b220-copd-3-331]). Additional studies have been published since these systematic reviews were published. [@b7-copd-3-331] noted that overall clinical response rate was improved with amoxicillin-clavulanate versus placebo in a multi-center trial in well-defined AECOPD; response clearly varied by the severity of baseline airflow obstruction, with the greatest difference between placebo and antimicrobial agent noted in patients with the lowest FEV~1~. Nouria and colleagues (2001) demonstrated dramatic improvement with ofloxacin therapy compared with placebo in a group of patients with severe COPD admitted with respiratory failure.

Based on data such as these, most recent international guidelines have incorporated recommendations as to which AECOPD patient is more likely to have bacterial infection likely to benefit from an antimicrobial agent ([@b31-copd-3-331]). Patients with at least two cardinal symptoms of an AECOPD (increase in dyspnea, increase in sputum production, and/or change in sputum color) experience a benefit with antibiotic therapy ([@b13-copd-3-331]). An exacerbation associated with sputum purulence may also be more likely to benefit from antibiotic treatment ([@b226-copd-3-331]; [@b263-copd-3-331]). Increasing sputum purulence has been clearly associated with bacterial growth in sputum samples ([@b8-copd-3-331]; [@b31-copd-3-331]). Measurement of serum procalcitonin levels have recently been suggested to define AECOPD patients with a higher likelihood of bacterial infection ([@b182-copd-3-331]; [@b37-copd-3-331]). Hence, the available data suggest that antimicrobial therapy provides benefit in carefully selected patients with more severe disease and more severe exacerbations.

Numerous controlled trials have compared newer agents with established ones. These studies have generally been designed as noninferiority trials for registrational purposes and therefore provide limited comparative information regarding clinical response for various antimicrobial classes ([@b141-copd-3-331]; [@b212-copd-3-331]; [@b263-copd-3-331]). Not surprisingly, clinical response in these trials is generally similar among different antimicrobial classes. However, more recent trials using novel experimental designs have suggested interesting differences between different antimicrobial classes. For example, in defining 'bacterial eradication' by sputum culture, [@b261-copd-3-331] noted that patients with persistent bacteria after a ten day course of antimicrobial therapy exhibited elevated sputum inflammatory markers. In addition, some investigators have suggested that a more rapid resolution of symptoms may be seen with quinolones in contrast to comparator agents ([@b139-copd-3-331]; [@b133-copd-3-331]). These data suggest that eradication of bacterial pathogens may be associated with important clinical outcomes.

The most provocative data have revolved around the finding that some agents may lengthen the disease-free interval (DFI), ie, the time between exacerbations ([@b14-copd-3-331]; [@b202-copd-3-331]; [@b35-copd-3-331]; [@b263-copd-3-331]). Because antimicrobial therapy that completely eradicates bacteria is associated with reduced inflammation ([@b261-copd-3-331]), such agents should result in greater symptomatic resolution and better long-term clinical outcomes ([@b14-copd-3-331]; [@b35-copd-3-331]; [@b263-copd-3-331]). Based on these considerations, AECOPD clinical trials have increasingly, incorporated an assessment of how different antibiotics affect the DFI ([@b133-copd-3-331]). An early study demonstrated equivalence between antibiotics in short-term clinical response, although post-hoc analysis suggested that failure to clear the organism from the sputum post-therapy was associated with a shorter DFI ([@b36-copd-3-331]). [@b266-copd-3-331] noted fewer recurrences of AECOPD with gemifloxacin (29%) compared to clarithromycin (41.5%, *P* = 0.016). The MOSAIC study investigators contrasted moxifloxacin with various comparators (cefuroxime, clarithromycin or amoxicillin) ([@b264-copd-3-331]). Although all antibiotics resulted in equivalent short-term clinical response, moxifloxacin-treated patients required fewer additional antibiotics and experienced a longer DFI. In contrast, [@b129-copd-3-331] did not demonstrate a difference between levofloxacin and clarithromycin with respect to the DFI, although the patient population was a bit less ill. Thus, the effect of antibiotic class on DFI remains a crucial endpoint for future studies of AECOPD.

In general, macrolides have provide adequate coverage for the most frequently identified pathogens in AECOPD ([@b132-copd-3-331]), although differences among the compounds in *H. influenzae* activity have been evident. For example, azithromycin appears to have improved bacteriologic and clinical activity relative to clarithromycin ([@b133-copd-3-331]). The role of the macrolides in AECOPD therapy remains controversial although they have been generally included in published guidelines ([@b19-copd-3-331]; Pauwels et al; [@b132-copd-3-331]; [@b268-copd-3-331]; [@b31-copd-3-331]). These guidelines usually advocate stratification of patients by likelihood of clinical failure, with macrolide therapy suggested for patients with milder underlying disease, a low likelihood of infection with organisms which are not covered with standard antibiotic regimens (eg, *P. aeruginosa*, drug-resistant bacteria), or host factors that predict treatment failure.

Macrolides as immunomodulatory agents
-------------------------------------

Macrolides are macrocyclical lactones consisting of greater than 8-membered rings. This very large class (\>2000 compounds) comprises both natural substances isolated from fungi and other organisms, as well as synthetic molecules of a similar structure ([@b98-copd-3-331]). The most commonly, clinically used agents are semi-synthetic 14-, 15-, or 16-membered ring antibiotics related to erythromycin ([Figure 1](#f1-copd-3-331){ref-type="fig"}). These include erythromycin, roxithromycin and clarithromycin as typical members of the 14-member class, and azithromycin as the prototypical 15-member compound ([@b126-copd-3-331]). Macrolide antibiotics bind to 50*S* ribosomes of both prokaryotes and eukaryotes, inhibiting transpeptidation or translocation of nascent peptides. Macrolides have good bioavailability by the oral route, superb tissue penetration, favorable side-effect profiles, and prolonged tissue persistence. For these reasons, and their broad efficacy against Gram-positive, some Gram-negative, mycobacterial, chlamydial, mycoplasmal, and *Legionella* species, macrolides are well established in the therapy of respiratory infections.

Macrolides exert broad-ranging immunomodulatory effects on mammalian cells in vitro and in vivo, as comprehensively reviewed by others and briefly summarized in Table 1 and illustrated in [Figure 2](#f2-copd-3-331){ref-type="fig"} ([@b276-copd-3-331]; [@b126-copd-3-331]; [@b247-copd-3-331]). Among their many activities, macrolides have been shown to exert effects on a wide range of cells including nasal and bronchial epithelial cells, alveolar macrophages, monocytes, eosinophils, neutrophils and lymphocytes. The effect on signaling pathways including NF-κB and AP-1 ([@b42-copd-3-331], [@b41-copd-3-331], [@b114-copd-3-331]) is evident in [Figure 2](#f2-copd-3-331){ref-type="fig"}. Macrolides exert a host of effects that collectively limit tissue damage by neutrophils. In addition to effects on chemoattractants, these include inhibiting their oxidant burst, impairing degranulation, and increasing the rate of neutrophil apoptosis. There is also evidence that macrolides decrease mucus viscosity ([@b241-copd-3-331]), and suppress angiogenesis ([@b274-copd-3-331]). Importantly, all these immunomodulatory effects are evident at concentrations attainable clinically by low-dose administration, and are not seen using 16-member macrolides. Most immunomodulatory effects are shared by the 14- and 15-member agents, although in some cases the effects vary among the individual compounds. For example, roxithromycin appears to exhibit consistent effects in vitro and in vivo ([@b4-copd-3-331]; [@b205-copd-3-331]). Similarly, clarithromycin and azithromycin induce apoptosis of peripheral blood lymphocytes to a qualitatively greater extent than josamycin ([@b93-copd-3-331]). Hence, macrolides have many properties that could mitigate the neutrophilic inflammation central to airway damage, and might also improve aspects of airflow obstruction.

Macrolides also exert diverse actions that suppress microbial virulence factors ([@b219-copd-3-331]; [@b175-copd-3-331]; [@b271-copd-3-331]). Although *P. aeruginosa* possesses high innate resistance in vitro (MIC ≥ 128 μg/ml), macrolides accumulate within the microbes over time, and suppress elaboration of elastase, lecithinase, and pyocyanin. Macrolides also alter the structure of LPS and outer membrane proteins, with a net effect of decreasing microbial adhesion to host cells. By in hibiting alginate production, macrolides destroy pseudomonal biofilm, facilitating killing by other antibiotics. Finally, sub-inhibitory concentrations of macrolides impede microbial motility of both *P. mirabilis* and *P. aeruginosa* by inhibiting flagellin synthesis. Importantly, these activities are also common to 14- and 15-ring macrolides, and have not seen using rokitamycin, a 16-member ring macrolide that has potent bactericidal activity against susceptible organisms. Furthermore, differences among individual agents have been reported with azithromycin exhibiting the greatest effect on quorum sensing ([@b145-copd-3-331]). Given these immunomodulatory properties and unique effects on bacterial pathogens macrolide antimicrobial agents have the potential to serve a unique role in the management of chronic inflammatory lung disorders, including COPD.

Macrolides in non-COPD chronic pulmonary inflammatory disorders
===============================================================

Macrolides have increasingly been used for their immunomodulatory properties in a wide range of chronic disorders. These will not be discussed in detail but results in chronic, inflammatory pulmonary disorders will be highlighted with a goal of presenting the rationale for their potential use in COPD.

Diffuse panbronchiolitis
========================

Diffuse panbronchiolitis (DPB) is a chronic inflammatory disorder of the respiratory bronchioles and adjacent centrilobular regions. It is seen mainly, but not exclusively, in Japan, and presents with chronic cough, exertional dyspnea, and reticulonodular infiltrates on chest radiography ([@b121-copd-3-331]). Chronic sinusitis is almost always noted. In fact, in geographical locations where this disease is found, the presence of airflow obstruction and chronic sinusitis in a nonsmoker should immediately raise suspicion of DPB. The appearance on high resolution computed tomography of the chest is characteristic ([@b6-copd-3-331]; [@b158-copd-3-331]). Early in the disease course, *H. influenzae* and *S. pneumoniae* are cultured from respiratory secretions, while in many cases *P. aeruginosa* is noted in advanced stages ([@b100-copd-3-331]).

The majority of investigators have confirmed a marked increase in neutrophils in BAL fluid of DPB patients ([@b87-copd-3-331]; [@b149-copd-3-331]; [@b101-copd-3-331]; [@b80-copd-3-331]). The percentage of neutrophils appears to be higher in DPB patients with *P. aeruginosa* infection ([@b166-copd-3-331]). Not unexpectedly, neutrophil chemotactic activity is markedly increased in DPB patients compared to normal, healthy volunteers ([@b102-copd-3-331]; [@b162-copd-3-331]). Similarly, DPB patients have high concentration of IL-8 in BAL fluid ([@b203-copd-3-331]), particularly in those infected with *P. aeruginosa* ([@b166-copd-3-331]). Importantly, the histologic pattern of DPB includes bronchiolar wall thickening with an infiltration of lymphocytes, plasma cells, and histiocytes ([@b84-copd-3-331]). Some investigative groups have noted that DPB patients have a higher number of lymphocytes and a reduced CD4/CD8 ratio compared to patients with idiopathic bronchiectasis and healthy subjects ([@b149-copd-3-331]). β-defensins have noted to be elevated in the BAL fluid of DPB patients, with the plasma concentration of β-defensin 2 (HBD-2) correlating with the concentration in BAL fluid ([@b80-copd-3-331]). All these findings support a central role for inflammation in the pathogenesis of DPB, and suggest that *Pseudomonas* involvement is at least associated with more severe involvement, and may contribute to an accelerated deterioration.

Prior to the onset of chronic macrolide therapy, the prognosis of DPB was dismal, with a 10 year survival of approximately 75% in cases without *P. aeruginosa* infection but less than 22% with *P. aeruginosa* infection ([@b121-copd-3-331]; [@b123-copd-3-331]). In the mid-1980's, Kudoh and colleagues first noted that erythromycin therapy improved outcome in DPB ([@b124-copd-3-331]; [@b125-copd-3-331]). Subsequent case series ([@b121-copd-3-331]) and a randomized, placebo-controlled trial confirmed this beneficial effect ([@b272-copd-3-331]). Importantly, this favorable effect was independent of the presence of *P. aeruginosa* infection ([@b204-copd-3-331]; [@b153-copd-3-331]) or the presence of chronic respiratory failure ([@b164-copd-3-331]). In addition to erythromycin, beneficial results have been confirmed with clarithromycin ([@b238-copd-3-331]), roxithromycin ([@b16-copd-3-331]; [@b155-copd-3-331]), and azithromycin ([@b116-copd-3-331]).

Increasing mechanistic insight on the clinical effects of macrolide therapy in DPB has become available. Improved symptoms, pulmonary function and arterial blood gases have been noted regardless of the presence of Pseudomonas infection, although there appears to be less marked improvement in pulmonary function in patients in whom bacteria persist after macrolide therapy, compared to those in whom sputum cultures become negative ([@b59-copd-3-331]). As such, the effect of macrolides is unlikely to exclusively reflect an antibacterial effect, as clinical improvement may be seen despite lack of change in bacterial isolates or number in at least 50% of treated patients ([@b100-copd-3-331]; [@b155-copd-3-331]).

Numerous investigators have demonstrated favorable effects of macrolide therapy on the inflammatory process in DPB. It is unlikely that the effect is purely a result of the antibacterial activity of the macrolide, because the maximal serum and sputum levels of erythromycin have been documented to be below the MICs of the clinically identified isolates (*H. influenzae* and *P. aeruginosa*) ([@b153-copd-3-331]). Supporting an anti-inflammatory effect, clinical treatment with a macrolide has been shown to decrease neutrophils ([@b87-copd-3-331]; [@b102-copd-3-331]; [@b162-copd-3-331]; [@b166-copd-3-331]; [@b59-copd-3-331]; [@b155-copd-3-331]; [@b80-copd-3-331]), neutrophil chemotactic activity ([@b102-copd-3-331]; [@b162-copd-3-331]), neutrophil-derived elastolytic-like activity ([@b87-copd-3-331]), and concentrations of IL-8 and LTB~4~ ([@b155-copd-3-331]). The latter has been shown to be independent of the ability to 'eradicate' organisms from sputum culture. However, patients in whom bacteria persist despite chronic macrolide therapy are less likely to experience improvement in BAL fluid neutrophil percentage ([@b59-copd-3-331]). In addition, macrolide therapy decreases the percentage of BAL lymphocytes and BAL concentration of HBD-2, which suggests a primary effect on the underlying pathogenic process ([@b80-copd-3-331]). In summary, these data confirm that marked beneficial effects are seen with macrolide therapy in DPB patients, and these effects likely reflect the anti-inflammatory properties of these agents and in addition to potential antimicrobial effects. The similarities to potential effects in COPD are evident.

Macrolides in asthma
--------------------

Asthma has a number of biological features that are distinct from COPD ([@b50-copd-3-331]; [@b232-copd-3-331]). Macrolide antibiotics have been utilized in asthma for more than forty years. For example, troleandomycin (TAO) was extensively studied as a steroid-sparing agent in asthma ([@b159-copd-3-331]), with inconclusive results ([@b55-copd-3-331]). Other investigators have examined more widely available macrolide agents. The most widely reported outcome has been a modest improvement in bronchial hyperresponsiveness ([@b143-copd-3-331]; [@b216-copd-3-331]; [@b104-copd-3-331]; [@b9-copd-3-331]; [@b120-copd-3-331]). Clinical response has been more difficult to judge in uncontrolled studies ([@b63-copd-3-331]). Several controlled trials have been published, as has a recent Cochrane systematic review ([@b184-copd-3-331]). In general, these studies have documented modest symptomatic improvement but little change in standard spirometric indices ([@b218-copd-3-331]; [@b9-copd-3-331]).

Other investigators have provided mechanistic data regarding the effect of macrolide therapy in patients with asthma. [@b122-copd-3-331] noted improved FEV~1~ in patients with evidence by polymerase chain reaction (PCR) of mycoplasma or chlamydia in upper or lower respiratory tract specimens (38/55 patients). PCR-positive patients treated with clarithromycin experienced a decrease in TNF-α, IL-5 and IL-12 mRNA in BAL fluid and TNF-α mRNA in airway tissue; PCR-negative patients treated with clarithromycin exhibited decreased TNF-α and IL-12 mRNA in BAL and TNF-α mRNA in airway tissue. No significant changes were seen in subjects treated with placebo. [@b28-copd-3-331] conducted a multicenter, multinational study of 232 adults with mild to moderate asthma and serological evidence of *C. pneumoniae* infection, randomizing patients to roxithromycin 150 mg bid or placebo for six weeks. A modest increase in peak expired flow was noted in the macrolide treated patients after six weeks; daytime and nighttime symptoms showed nonsignificant improvements, as did improved quality of life scores. The differences between these two studies may reflect disparity in patient characteristics at baseline, differing macrolides administered, and differing definition of an atypical infection. These points may be important in interpreting data in COPD patients, in whom chronic infection with *Chlamydia* has been felt to be important ([@b29-copd-3-331]).

Macrolides in noncystic fibrosis bronchiectasis
-----------------------------------------------

Bronchiectasis is a disorder of the bronchi and bronchioles manifesting cough, chronic sputum production, dyspnea, and wheezing ([@b23-copd-3-331]). The cornerstones of therapy include early identification and treatment of acute exacerbations, suppression of the microbial load, treatment of underlying conditions, promotion of bronchial hygiene, control of bronchial hemorrhage, surgical resection of extremely damaged/focal disease and reduction of excessive pulmonary inflammation ([@b23-copd-3-331]).

It is likely that bronchiectasis involves a vicious cycle of infection with subsequent inflammation and mediator release. Investigators have confirmed an intense cellular infiltrate with mononuclear cells (CD4+ T lymphocytes and macrophages), a prominent neutrophilia and increased IL-8 expression ([@b61-copd-3-331]). Increased expression of IL-8 and other potent chemoattractants (TNF-α and LTB~4~) have also been reported ([@b12-copd-3-331]; [@b185-copd-3-331]; [@b248-copd-3-331]). In addition, patients colonized with potentially pathogenic organisms experience a greater inflammatory response which includes higher BAL neutrophil count and higher BAL concentrations of elastase, myeloperoxidase, TNF-α and IL-8 ([@b12-copd-3-331]).

Bronchiectasis patients with *P. aeruginosa* in the sputum have more severely impaired pulmonary function and greater sputum volume ([@b82-copd-3-331]). These patients also appear to exhibit the highest concentration of TNF-α and LTB~4~ ([@b248-copd-3-331]). It is evident that bronchiectasis is characterized by augmented airway inflammation that appears related to bacterial colonization, organism load and differing bacterial species.

A small number of studies have examined the effect of chronic macrolide therapy in bronchiectasis unrelated to cystic fibrosis. After 12 weeks of roxithromycin (4 mg/kg bid) children with bronchiectasis and increased airway hyperreactivity experienced little change in FEV~1~ but experienced improvement in sputum purulence and airway responsiveness ([@b118-copd-3-331]). In a placebo-controlled trial, [@b250-copd-3-331] administered erythromycin (500 mg bid) for eight weeks to 11 patients with bronchiectasis ([@b250-copd-3-331]). *P. aeruginosa* was identified at baseline in ten of the patients and *H. influenzae* in the eleventh. Patients treated with macrolides experienced an improvement in spirometry and 24-hour sputum volume, but no parallel improvement in sputum pathogens, sputum leukocytes, or levels of IL-1α, IL-8, TNF-α or LTB~4~ ([@b250-copd-3-331]). [@b236-copd-3-331] noted improved sputum production in 16 patients with bronchiectasis (n = 11) or chronic bronchitis (n = 5) treated with clarithromycin (400 mg/day) compared to patients treated with amoxicillin or cefaclor. [@b40-copd-3-331] examined thrice weekly (after initial loading) azithromycin therapy in 39 patients with bronchiectasis, greater than four exacerbations in the previous 12 months, and persistent symptoms. Only modest improvements were noted in pulmonary function, although symptoms scores and acute exacerbations decreased; these findings were independent of *P. aeruginosa* colonization. In a small, cross-over study, [@b39-copd-3-331] noted a decrease in acute exacerbation rate and mean 24-hour sputum volume, but no change in pulmonary function with twice weekly azithromycin therapy for six months. These data are particularly germane, given the frequent development of bronchiectasis following AECOPD ([@b161-copd-3-331]).

Macrolides in cystic fibrosis
=============================

A robust body of literature has emerged demonstrating that macrolide antibiotics are beneficial in the treatment of cystic fibrosis (CF) lung disease ([@b54-copd-3-331]; [@b267-copd-3-331]; [@b199-copd-3-331]; [@b223-copd-3-331]). Numerous studies have strengthened the conclusion that there is excessive inflammation in CF airways. [@b113-copd-3-331] noted higher inflammatory cells and mediators in infants with CF, even when no evidence of bacterial infection was identified. This augmented inflammatory response may be intrinsic to CF airway epithelial cells, as [@b48-copd-3-331] noted that in response to Pseudomonas, epithelial cells having mutations in the cystic fibrosis gene (CFTR) elaborated higher levels of inflammatory mediators than cells with normal CFTR.

As with other inflammatory pulmonary disorders, a high prevalence of chronic airway infection occurs in CF. *P. aeruginosa* appears to be the most prevalent organism, with 80% of patients infected by 18 years of age ([@b245-copd-3-331]). This infection has major consequences, as the survival of CF patients harboring *Pseudomonas aeruginosa* is shorter than that of CF patients uninfected by *Pseudomonas*.

A series of studies have confirmed the benefit of macrolide therapy in CF. [@b97-copd-3-331] performed an open-label study of daily azithromycin in children with CF in the UK, noting a modest improvement in spirometry with azithromycin therapy. The first well-constructed clinical trial of azithromycin in CF was reported by [@b267-copd-3-331]. Sixty CF patients (mean age 27.9 years) were randomly assigned in a double-blind fashion to 250 mg azithromycin daily or placebo for 3 months. A modest improvement favoring the macrolide was noted in spirometry, the requirement for intravenous antibiotic treatment for acute exacerbations, and quality of life. [@b54-copd-3-331] performed a randomized, double-blind, placebo-controlled, crossover study of 41 CF patients (age range 8--18 years). Patients received daily azithromycin adjusted to body weight or placebo for 6 months. After a 2-month washout period, patients were crossed over to the alternative therapy for 6 months. A modest improvement in FEV~1~ was noted favoring azithromycin; however, there was no difference in FVC, FEF~25--75~, pulmonary exacerbation rate, antibiotic use, changes in exercise tolerance, quality of well-being, bacterial culture densities, or sputum levels of interleukin-8 and neutrophil elastase.

The largest trial of macrolide therapy in CF was completed by [@b199-copd-3-331], who performed a multi-centered, randomized, double-blinded, placebo-controlled study of 185 patients ≥6 years of age who were chronically infected with *P. aeruginosa* and had a percent predicted FEV~1~ ≥30. Patients were treated with weight-adjusted azithromycin dosage. After 24 weeks treatment, the percent predicted FEV~1~ improved in the azithromycin group (4.4%), whereas it declined in the placebo group (1.8%, p = 0.001). Furthermore, azithromycin-treated patients were less likely to experience an exacerbation than those treated with a placebo (HR 0.65, 95% CI 0.44--0.95, p = 0.03). Subsequent post-hoc analyses confirmed that the improvement in secondary endpoints was independent of the change in FEV~1~ ([@b200-copd-3-331]).

The mechanism for this favorable macrolide effect remains controversial and is likely multifactorial ([@b134-copd-3-331]). There is growing evidence that macrolides may be beneficial by directly altering *P. aeruginosa* biology ([@b96-copd-3-331]; [@b156-copd-3-331]; [@b255-copd-3-331]). Suggested mechanisms include: (1) microbicidal effects on *P. aeruginosa* that are in stationary as opposed to exponential growth phase; (2) reduction in the elaboration of virulence factors; (3) alteration in biofilm formation; (4) decrease in bacterial adherence to epithelial cells; (5) inhibition of bacterial motility; and (6) providing a synergistic effect to other antibiotics ([@b134-copd-3-331]). It is likely that beneficial anti-inflammatory effects also play a role ([Table 1](#t1-copd-3-331){ref-type="table"}) ([@b96-copd-3-331]; [@b156-copd-3-331]; [@b134-copd-3-331]).

Macrolides in chronic obstructive pulmonary disease
===================================================

Taken together, the available data confirm that a macrolide can result in clinical improvement in patients with severe, chronic inflammatory lung diseases associated with frequent bacterial colonization and chronic infection. These data provide a rationale for expansion of the study of macrolide therapy to other, more common, inflammatory airway disorders, including COPD. Given the importance of inflammation and bacterial infection in the pathogenesis of COPD and its exacerbations, it is evident that macrolides may offer unique advantages as disease-modifying agents and that such an effect could be multifactorial ([Figure 3](#f3-copd-3-331){ref-type="fig"}).

This possibility is supported by three older published studies. First, a randomized trial contrasting moxifloxacin with clarithromycin in acute exacerbations confirmed clinical response to clarithromycin in 88.4% of patients, despite achieving bacteriologic eradication in only 48.8% ([@b265-copd-3-331]). An immunomodulatory effect of the macrolide was suggested to explain this discrepant finding ([@b263-copd-3-331]). Second, [@b234-copd-3-331] reported results of an open-label, prospective randomized trial of erythromycin therapy (200--400 mg/day) versus riboflavin (10 mg/day) for twelve months in COPD patients (FEV~1~ \~ 1.4 liters). During the course of therapy, the risk and frequency of experiencing a common cold using a predefined, standardized definition and subsequent acute exacerbations were prospectively evaluated. [Table 2](#t2-copd-3-331){ref-type="table"} enumerates the significant benefits noted with macrolide therapy. Although the results are intriguing, the unblinded data collection limits the strength of the conclusions in this study.

Third, [@b65-copd-3-331] identified 54 patients with a long history of chronic bronchitis (\>10 years), a frequency more than five episodes per year, and at least two respiratory hospitalizations in the previous year. Patients were treated with azithromycin 500 mg daily for three days every 21 days from September through May and were compared to a similar, retrospective group of untreated COPD patients. Although there were no baseline differences between the treated patients and the control patients, over the course of follow-up macrolide treated patients experienced fewer exacerbations and hospitalizations per year ([Table 3](#t3-copd-3-331){ref-type="table"}). Not unexpectedly, during exacerbations the azithromycin treated group experienced infection with *S. pneumoniae* (n = 21), *P. aeruginosa* (n = 6), and *K. pneumoniae* (n = 3). Interestingly, within the first 15 days of prophylactic treatment, 21 of these exacerbations were caused by *S. pneumoniae* isolates with diminished susceptibility to macrolides and penicillins. In the control group, the predominant isolates during an exacerbations included *H. influenzae* (n = 29) and *S. pneumoniae* (n = 9; two exhibiting diminished sensitivity to azithromycin). This study, although using a suboptimal, uncontrolled design, suggests that a beneficial response can be seen with chronic macrolide prophylaxis in high-risk COPD patients. The mechanism of improvement was not addressed, but could be related to the antibacterial activity (particularly with regards to *H. influenzae*).

More recently, two groups have reported small controlled studies. [@b25-copd-3-331] randomized 30 stable male COPD patients (mean age \~69 yrs, FEV~1~\~ 36% predicted) to clarithromycin (500 mg bid) or placebo for two weeks in addition to standardized bronchodilator therapy. Although no baseline differences were noted between the treatment groups, clarithromycin-treated patients experienced significantly improved sputum inflammatory markers ([Figure 4](#f4-copd-3-331){ref-type="fig"}), whereas physiologic studies did not change. The results of serum inflammatory markers were qualitatively similar in the two groups. In a second controlled study, 67 patients with moderate to severe COPD (mean age \~ 67 yrs, FEV~1~ \~43% pred) were randomized to three months of clarithromycin (500 mg of sustained release preparation daily) or placebo ([@b21-copd-3-331]). In contrast to the previous study, all patients were taking inhaled corticosteroids. Clarithromycin was associated with a significant improvement in the St. George's Respiratory Questionnaire (SGRQ) symptom score (10.2 units) and the SF-36 Physical Function Score (12.9 units) but no difference in overall SGRQ score, shuttle walk distance, spirometry or CRP levels. During the relatively short time of follow-up there were five total AECOPDs (3 in the clarithromycin and 2 in the placebo group). No difference was seen in quantitative sputum cultures obtained in the stable state ([Figure 5](#f5-copd-3-331){ref-type="fig"}). In contrast to the previous study, sputum IL-8, TNF-α, or LTB~4~ levels did not differ between clarithromycin versus placebo treatment, although there was a modest macrolide-associated improvement in sputum neutrophil differential and neutrophil chemotaxis ([@b21-copd-3-331]).

Other investigators have proposed mechanistic rationale for improvement with chronic macrolide therapy in COPD patients. [@b236-copd-3-331] suggested that chronic bronchitis or bronchiectasis patients treated with clarithromycin (400 mg qd for seven days) experienced greater decrease in sputum volume than patients treated with a β-lactam. [@b171-copd-3-331] treated 16 COPD patients (mean FEV~1~ 1.8 liters) with azithromycin (500 mg daily) for three days and eight with placebo. Azithromycin resulted in an early transient increase in overall nitrite plus nitrate concentration, but later (days 11--18) decreases in total blood leukocyte count, serum CRP, IL-8- and oxidative burst of isolated blood granulocytes. No difference was noted in sputum inflammatory markers between azithromycin- treated and placebo-treated patients.

There is potential risk to chronic macrolide therapy in this patient population. Macrolide use may be associated with an increased risk of subsequent infection with macrolide nonsusceptible bacteria, particularly *S. pneumoniae* ([@b115-copd-3-331]; [@b253-copd-3-331]). An increase in macrolide-nonsusceptible *S. pneumoniae* has been reported with chronic erythromycin ([@b2-copd-3-331]; [@b108-copd-3-331]), clarithromycin ([@b108-copd-3-331]) and azithromycin therapy ([@b65-copd-3-331]; [@b2-copd-3-331]). Similarly, these agents may be associated with gastrointestinal intolerance ([@b199-copd-3-331]; [@b25-copd-3-331]; [@b39-copd-3-331]), cardiac toxicity ([@b86-copd-3-331]; [@b137-copd-3-331]), and ototoxicity ([@b77-copd-3-331]; [@b235-copd-3-331]; [@b256-copd-3-331]). The frequency and severity of these toxicities varies with the agent, the dose and duration of therapy. These potential complications and the high prevalence of medical comorbitidies in COPD patients highlight the potential risk of chronic empiric macrolide therapy in this patient population.

Conclusions
===========

Macrolide antibiotics have assumed an important role in the management of AECOPDs because of their broad-spectrum coverage and excellent safety profile. Increasingly, data are becoming available that macrolides have beneficial effects that are independent of their antibacterial activity. These potent anti-inflammatory effects may be particularly important in chronic inflammatory airway disorders. These latter actions may be of greatest benefit for selected patients with COPD, a disorder characterized by augmented pulmonary inflammation at baseline, frequent bacterial colonization/infection, and recurrent exacerbations of disease which further increase lung inflammation.

The role of chronic macrolide therapy in these patients requires additional study to better define a series of concerns, including:

-   What is the treatment-effect of chronic macrolide therapy in COPD patients treated maximally with conventional therapies?

-   Do macrolides attenuate baseline inflammation or do they prevent or attenuate AECOPD episodes?

-   Does the therapeutic effect reflect antimicrobial activity, an immunomodulatory effect, or both?

-   Does the therapeutic effect vary by host factors, including disease severity, presence of bronchiectasis, presence of baseline colonization with typical (including *P. aeruginosa*) or atypical pathogens (including *C. pneumoniae*), or the presence of comorbidity?

-   What is the toxicity of chronic therapy in COPD patients?

-   What is the risk-benefit of macrolide therapy in COPD patients?

Resolution of these vital questions will require additional, well-designed, placebo-controlled trials. To our knowledge three large studies are currently ongoing which should yield answers to all or most of these vital questions before widespread use of macrolide prophylaxis can be recommended in COPD patients.
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![Levels of induced-sputum inflammatory markers in clarithromycin- and placebo-treated COPD patients before and after treatment. AT, after treatment; BT, before treatment; IL-8, interleukin-8; LTB~4~, leukotriene B4; TNF-α, tumor necrosis factor-α. \*p \< 0.05 before versus after treatment. Copyright © 2004. Reproduced with permission from [@b25-copd-3-331]. The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. *Ann Pharmacother*, 38:783--92.](copd-3-331f4){#f4-copd-3-331}

![The effect of clarithromycin and placebo on sputum colony forming units (Cfu) numbers/bacterial (PPM) isolate. Cfu numbers are logged. Weighted bars indicate the mean for the whole group. There was no statistically significant difference between pre- and post-therapy Cfu numbers for both clarithromycin and placebo groups. NS indicates not significant. Copyright © 2004. Reproduced with permission from [@b21-copd-3-331]. The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial. *Treat Respir Med*, 3:59--65.](copd-3-331f5){#f5-copd-3-331}

###### 

Anti-inflammatory and bacterial virulence effects of macrolide antibiotics

  Author, Year                                                                                                                                                   Effect
  -------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------
  [@b92-copd-3-331]; [@b166-copd-3-331]; [@b240-copd-3-331]; [@b119-copd-3-331]; [@b114-copd-3-331]; [@b237-copd-3-331]; [@b41-copd-3-331]; [@b181-copd-3-331]   Down regulates TNF-α, IL-1, IL-4, IL-8 expression by various cell types
  [@b94-copd-3-331]                                                                                                                                              ↑ production of β-defensin-1 and β-defensin-2 by epithelial cells
  [@b254-copd-3-331]                                                                                                                                             ↓ superoxide and elastase release from stimulated PMNs
  Shimane 1997; [@b112-copd-3-331]; [@b233-copd-3-331]; [@b237-copd-3-331]                                                                                       ↓ stimulated release of IL-1β, IL-6, GM-CSF, and TNF-γ
  [@b76-copd-3-331]; [@b105-copd-3-331]                                                                                                                          ↓ matrix metalloproteinase-9 expression and activity
  [@b148-copd-3-331]                                                                                                                                             ↓ IL-5-induced increases in eosinophil survival
  [@b110-copd-3-331]; [@b15-copd-3-331]; [@b3-copd-3-331]; [@b91-copd-3-331]; [@b163-copd-3-331]; [@b103-copd-3-331]                                             ↑ neutrophil, lymphocyte, histiocyte and eosinophil apoptosis
  [@b162-copd-3-331]; [@b246-copd-3-331]                                                                                                                         ↓ neutrophil chemotaxis
  [@b38-copd-3-331]; [@b273-copd-3-331]                                                                                                                          ↓ neutrophil survival
  [@b187-copd-3-331]; [@b217-copd-3-331]; [@b90-copd-3-331]                                                                                                      ↓ mucus secretion
  [@b127-copd-3-331]; [@b58-copd-3-331]; [@b89-copd-3-331]                                                                                                       ↓ methylprednisolone elimination
  [@b26-copd-3-331]; [@b249-copd-3-331]                                                                                                                          ↓ *P. aeruginosa* adherence and outer membrane function
  [@b116-copd-3-331]; [@b88-copd-3-331]; [@b239-copd-3-331]; [@b243-copd-3-331]; [@b154-copd-3-331]; [@b64-copd-3-331]; [@b255-copd-3-331]                       ↓ alginate, biofilm formation and quorum sensing
  [@b109-copd-3-331]                                                                                                                                             ↓ flagellin

**Abbreviations:** IL, GM-CSF, TNF-α, PMN.

###### 

Effect of 12 months of erythromycin therapy on common colds and AECOPDs in patients with COPD

  Outcome                                            Treatment group   p value   
  -------------------------------------------------- ----------------- --------- ----------
  Total common colds, N                              245               67        0.0002
  Total number of exacerbations, N                   64                14        \<0.0001
  Mild/moderate exacerbations                        53                14        0.0087
  Severe                                             11                0         0.0007
  Total patients with one or more exacerbations, N   30                67        \<0.0001
  Mild/moderate                                      20                6         0.0004
  Severe                                             10                0         0.0004

Copyright © 2001. Reproduced with permission from [@b234-copd-3-331]. Erythromycin and common cold in COPD. *Chest*, 120:730--3.

###### 

Effect of azithromycin prophylactic therapy in COPD patients at high risk of AECOPD and treatment failure

  Outcome                 Treatment group   p value   
  ----------------------- ----------------- --------- ---------
  Exacerbations/year      187               249       30.0001
  Hospitalizations/year   22                45        30.05

Copyright © 2000. Reproduced with permission from [@b65-copd-3-331]. Estudio prospective y comparative (1994--1998) sobre la influencia del tratamiento corto profilactico con azitromicina en pacientes con EPOC evolucionada. Rev Esp Quimioterap, 13:379--83.
